Onglyza Lawsuit Information Center
Where you or a loved one harmed by Onglyza? This Type 2 diabetes drug may be associated with some very serious complications, including heart failure, pancreatitis and pancreatic cancer. The nationwide law firm of Bernstein Liebhard LLP is currently evaluating potential Onglyza lawsuit, and would like to hear from you if you or someone you care about took Onglyza or Kombiglyze XR and were diagnosed with heart failure or other side effects potentially associated with their use. Our attorneys may be able to help you obtain financial compensation for any injury-related damages you incurred, including medical expenses, lost wages, pain and suffering, and more.
Onglyza Side Effects
Onglyza or Kombiglyze XR are both DPP-4 inhibitors, and belong to a class of Type 2 diabetes medications called incretin mimetics. Both contain the active ingredient saxagliptin, and work by increasing the amount of incretin released by the intestine. Incretin plays an important role in regulating the amount of insulin secreted by the pancreas. In addition to saxagliptin, Kombiglyze XR also contains metformin and is an extended release medication. Onglyza was approved by the U.S. Food and Drug Administration (FDA) in 2009, and Kombiglyze XR was approved in 2010. Onglyza sales reached $709 million in 2012, and some analysts believe annual sales of the drug could reach $2.47 billion by 2018.
In February 2014, the FDA issued a safety alert after a clinical trial published in the New England Journal of Medicine linked Onglyza to a 27% increased risk of hospitalization for heart failure. The goal of the 16,492-patient study was to see if saxagliptin could provide heart-protective benefits in addition to controlling blood glucose levels. In April 2015, the FDA convened an advisory panel meeting to further investigate the link between Onglyza and heart failure. The panel voted 14-1 to recommend that new safety information regarding an increased risk of heart failure be added to the labels of both Onglyza and Kombiglyze XR.
According to the FDA, there have been reports of acute pancreatitis in patients taking Onglyza. Saxagliptin should not be prescribed to people who have a history of pancreatitis (inflammation of the pancreas) because it is not known whether the medication can increase the risk for the disease. In 2013, the FDA also launched an investigation of incretin mimetics like Onglyza and pancreatic cancer, after a small study linked the drugs to precancerous changes in the pancreas. While no Onglyza lawsuits have been filed over this possible complication, several other incretin mimetic medications are the subject of pancreatic cancer litigation.
Learn More about Filing an Onglyza Lawsuit
If you are interested in filing an Onglyza lawsuit for heart failure or other complications potentially associated with this medication, please contact our attorneys today. They can explain the process for pursuing a legal claim against the drug’s manufacturers, and can advise you of all of your legal options. For your free, no-obligation case review, please call .